Surface Functionalization of Doxorubicin loaded MCM-41 Mesoporous Silica Nanoparticles by 3-Aminopropyltriethoxysilane for Selective Anticancer 9 Effect on A549 and A549/DOX Cells

Abstract

In this study, MCM-41 mesoporous silica nanoparticles were successfully synthesized by the condensation of a tetraorthosilicate precursor on a template self-assembled by cetyltrimethylammonium bromide in alkaline. The small-angle x-ray diffraction patterns of MCM-41 indicate that silica nanoparticles possess hexagonal structures with a high degree of structural ordering. Transmission electron microscopy images show that the size of the MCM-41 particles is around 100-120 nm, and the pore sizes range from 2 nm to 4 nm. In addition, the specific surface area of MCM-41 obtained by Brunauer-Emmett-Teller analysis is as high as 987 m 2 .g À1 and the pore size extracted from nitrogen physical adsorption isotherms is in accordance with the TEM result. Thermogravimetric analysis, Fourier-transform infrared spectroscopy, Zeta potential measurements and photoluminescence measurements show that 3-aminopropyltriethoxysilane (APTES) and doxorubicin were grafted and loaded successfully onto MCM-41 nanoparticles. An assay on fibroblasts, A549 and doxorubicin-resistant A549/DOX cells indicates that the prepared MCM41 grafting APTES nanoparticles are safe to normal cells and toxic to cancer cells in vitro.

Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy

“…The encapsulation efficiency (EE%) and drug loading capacity (LC%) were about 98.65% ± 0.88 and 49.79% ± 1.03, respectively according to the data obtained by UV/Vis spectroscopy. In the FTIR spectra, absorption peaks at 3436 and 1728 cm −1 were observed due to additional hydroxyl and carbonyl groups, respectively [ 31 ] verifying the effective loading of DOX on the silica pores. The zeta potential and particle size were recorded around − 10.55 ± 1.00 mV and 7.92 ± 3.33 nm, respectively for NPs@DOX formula.…”

Sustained release of alpha‐methylacyl‐CoA racemase (AMACR) antibody‐conjugated and free doxorubicin from silica nanoparticles for prostate cancer cell growth inhibition

“…where L 0 corresponds to the length over the flux boundary. At steady state, the average flux can be obtained from Equation (21). The effective diffusion was also obtained from.…”

“…Mesoporous silica nanoparticles have been widely studied as sustained release cancer drug nanocarriers to inhibit cancer cell growth 17–21 . This is due to their unique properties, such as high total specific surface area, high pore volume, large loading capacity, biocompatibility, and easy surface modification 21 …”

“…[13][14][15][16] Mesoporous silica nanoparticles have been widely studied as sustained release cancer drug nanocarriers to inhibit cancer cell growth. [17][18][19][20][21] This is due to their unique properties, such as high total specific surface area, high pore volume, large loading capacity, biocompatibility, and easy surface modification. 21 Alpha-methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme involved in the beta-oxidation of dietarybranched fatty acids and C-27 bile acid intermediates.…”

“…[17][18][19][20][21] This is due to their unique properties, such as high total specific surface area, high pore volume, large loading capacity, biocompatibility, and easy surface modification. 21 Alpha-methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme involved in the beta-oxidation of dietarybranched fatty acids and C-27 bile acid intermediates. 22 Analyses of 22 studies involving 4385 participants concluded that AMACR proteins are overexpressed in PCs compared to lower expression in normal and benign prostatic tissue.…”